[Skip to Content]
[Skip to Content Landing]
Views 805
Citations 0
Comment & Response
May 18, 2020

Minocycline—A Lesson From a Failure

Author Affiliations
  • 1Center for Advanced Studies and Technology, University G. d’Annunzio of Chieti-Pescara, Chieti, Italy
JAMA Neurol. Published online May 18, 2020. doi:10.1001/jamaneurol.2020.1154

To the Editor The development of novel and effective strategies aimed at modifying the course of Alzheimer disease (AD) is urgently needed. In a recent double-blind randomized clinical trial, Howard and colleagues1 reported that minocycline, a broad-spectrum antibiotic, failed to provide clinical benefits (as assessed by changes in scores of the Mini-Mental State Examination and the Bristol Activities of Daily Living scale) in a cohort of persons with a diagnosis of early AD. The rationale for the investigation of minocycline stems from preclinical evidence supporting the notion that the drug targets critical determinants of AD-like β-amyloid, hyperphosphorylated tau, and microglia activation and neuroinflammation.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words